Updated just now · Live
Stock analysis, price data, and AI-powered insights for Prelude Therapeutics Inc (PRLD).
Prelude Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for PRLD.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). PRLD Stock Intelligence Report. [stoxpulse.com/stocks/prld]
Disclaimer: The information on this page about Prelude Therapeutics Inc (PRLD) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Prelude Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Prelude Therapeutics shares are trading higher aft...
1d ago
Prelude Therapeutics Prices $90M Offering of 18M S...
1d ago
StoxPulse AI results for PRLD: Pulse Score 54/100. Primary sentiment trends from 7 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$284.1M
P/E Ratio
—
EPS
$-0.26
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from its lead development candidate, PRT13722. The company price a $90 million offering of 18 million shares at $4.44 per share.
Prelude Therapeutics Prices $90M Offering of 18M Shares At $4.44 Per Share
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Prelude Therapeutics Announces Presentation Of New Preclinical Data From PRT13722 For The Treatment Of Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Breast Cancer, And Believes That PRT13722 Is A Highly Differentiated, First-In-Class, Orally Bioavailable, Potent And Highly-selective Kat6A Degrader
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer